{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:32:50Z","timestamp":1792787570046,"version":"4.5.0"},"reference-count":47,"publisher":"American Association for Cancer Research (AACR)","issue":"20","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Immuneering Corporation","id":[{"id":"https:\/\/ror.org\/00awq8a10","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Inappropriate activation of the mitogen-activated protein kinase (MAPK) pathway, often stemming from activating mutations in RAS or RAF, represents one of the most common oncogenic events in human cancer. However, currently approved RAS\/RAF inhibitors target specific mutants that are only present in a small proportion of RAS- or RAF-activated tumors. Current MEK inhibitors (MEKi) are associated with class-effect toxicities and tumor escape via CRAF bypass of MEK blockade. To address these issues, we designed atebimetinib to resist CRAF-mediated bypass and enable a pharmacokinetic\/pharmacodynamic profile termed deep cyclic inhibition (DCI), an approach that transiently but deeply suppresses oncogenic signaling while allowing daily physiologic reset. Unlike chronic or intermittent approaches, DCI optimizes depth and duration of MEK suppression on a daily cycle, blunting rebound signaling while preserving recovery windows for normal tissues. Functioning as an allosteric, selective MEKi, atebimetinib potently inhibited ERK phosphorylation in vitro and in vivo, resisted CRAF bypass, and was well tolerated and more efficacious in xenograft models of cancer compared with current MEKis. Overall, these findings establish atebimetinib as a dual-MEKi with the potential to provide mutation-agnostic inhibition of the MAPK pathway while leveraging DCI, designed to avoid toxicities associated with existing MEKis. Atebimetinib offers MEK inhibition that is durable and tolerable, supporting the potential of this therapeutic paradigm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Atebimetinib, a deep cyclic inhibitor of MEK, blocks MAPK signaling, resists RAF bypass, and is active in RAS- and RAF-mutant tumors, representing a mechanistically differentiated approach in the field of targeted therapies.<\/jats:p>\n                    <jats:p>See related commentary by Gaire and Poulikakos, p. 5017<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-25-4907","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:02:04Z","timestamp":1784642524000},"page":"5223-5237","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in\n                    <i>RAS<\/i>\n                    - and\n                    <i>RAF<\/i>\n                    -Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass"],"prefix":"10.1158","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7596-6765","authenticated-orcid":false,"given":"Sarah","family":"Kolitz","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00awq8a10","id-type":"ROR","asserted-by":"publisher"}],"name":"Immuneering Corporation 1 , Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7572-1662","authenticated-orcid":false,"given":"Anna","family":"Travesa","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00awq8a10","id-type":"ROR","asserted-by":"publisher"}],"name":"Immuneering Corporation 2 , San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7039-3469","authenticated-orcid":false,"given":"Amy","family":"Axel","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00awq8a10","id-type":"ROR","asserted-by":"publisher"}],"name":"Immuneering Corporation 2 , San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3903-7585","authenticated-orcid":false,"given":"Jason M.","family":"Funt","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00awq8a10","id-type":"ROR","asserted-by":"publisher"}],"name":"Immuneering Corporation 2 , San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0752-8030","authenticated-orcid":false,"given":"Matthew S.","family":"Nord","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00awq8a10","id-type":"ROR","asserted-by":"publisher"}],"name":"Immuneering Corporation 2 , San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7884-7633","authenticated-orcid":false,"given":"Amy","family":"Yamamura","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00awq8a10","id-type":"ROR","asserted-by":"publisher"}],"name":"Immuneering Corporation 2 , San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5609-5725","authenticated-orcid":false,"given":"Kevin D.","family":"Fowler","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00awq8a10","id-type":"ROR","asserted-by":"publisher"}],"name":"Immuneering Corporation 2 , San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6800-5552","authenticated-orcid":false,"given":"Praveen","family":"Nair","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00awq8a10","id-type":"ROR","asserted-by":"publisher"}],"name":"Immuneering Corporation 2 , San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7223-9760","authenticated-orcid":false,"given":"Benjamin","family":"Zeskind","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00awq8a10","id-type":"ROR","asserted-by":"publisher"}],"name":"Immuneering Corporation 3 , New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2290-0814","authenticated-orcid":false,"given":"Brett M.","family":"Hall","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00awq8a10","id-type":"ROR","asserted-by":"publisher"}],"name":"Immuneering Corporation 2 , San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9395-9014","authenticated-orcid":false,"given":"Peter","family":"King","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00awq8a10","id-type":"ROR","asserted-by":"publisher"}],"name":"Immuneering Corporation 2 , San Diego, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"2026101503085406100_bib1","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The frequency of ras mutations in cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res"},{"key":"2026101503085406100_bib2","doi-asserted-by":"publisher","first-page":"e2100245","DOI":"10.1200\/PO.21.00245","article-title":"Landscape of KRAS(G12C), associated genomic alterations, and interrelation with immuno-oncology biomarkers in KRAS-mutated cancers","volume":"6","author":"Salem","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"2026101503085406100_bib3","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1002\/cncr.26724","article-title":"NRAS mutation status is an independent prognostic factor in metastatic melanoma","volume":"118","author":"Jakob","year":"2012","journal-title":"Cancer"},{"key":"2026101503085406100_bib4","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"2026101503085406100_bib5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/PPO.0b013e31824b436e","article-title":"Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies","volume":"18","author":"Kudchadkar","year":"2012","journal-title":"Cancer J"},{"key":"2026101503085406100_bib6","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"2026101503085406100_bib7","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"2026101503085406100_bib8","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.3390\/cancers12071823","article-title":"BRAF inhibitors: molecular targeting and immunomodulatory actions","volume":"12","author":"Proietti","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026101503085406100_bib9","doi-asserted-by":"publisher","first-page":"e000491","DOI":"10.1136\/esmoopen-2019-000491","article-title":"Tolerability of BRAF\/MEK inhibitor combinations: adverse event evaluation and management","volume":"4","author":"Heinzerling","year":"2019","journal-title":"ESMO Open"},{"key":"2026101503085406100_bib10","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.3390\/cancers11101618","article-title":"A comprehensive review on MAPK: a promising therapeutic target in cancer","volume":"11","author":"Braicu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2026101503085406100_bib11","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3389\/fphys.2012.00475","article-title":"How scaffolds shape MAPK signaling: what we know and opportunities for systems approaches","volume":"3","author":"Witzel","year":"2012","journal-title":"Front Physiol"},{"key":"2026101503085406100_bib12","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nature08314","article-title":"A dimerization-dependent mechanism drives RAF catalytic activation","volume":"461","author":"Rajakulendran","year":"2009","journal-title":"Nature"},{"key":"2026101503085406100_bib13","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/onc.2012.160","article-title":"Mechanisms of acquired resistance to ERK1\/2 pathway inhibitors","volume":"32","author":"Little","year":"2013","journal-title":"Oncogene"},{"key":"2026101503085406100_bib14","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1016\/j.biocel.2008.04.009","article-title":"The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells","volume":"40","author":"Ramos","year":"2008","journal-title":"Int J Biochem Cell Biol"},{"key":"2026101503085406100_bib15","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrc4000","article-title":"MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road","volume":"15","author":"Caunt","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"2026101503085406100_bib16","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ccr.2014.03.011","article-title":"Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors","volume":"25","author":"Lito","year":"2014","journal-title":"Cancer Cell"},{"key":"2026101503085406100_bib17","doi-asserted-by":"publisher","first-page":"eaao3048","DOI":"10.1126\/science.aao3048","article-title":"Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway","volume":"361","author":"Bugaj","year":"2018","journal-title":"Science"},{"key":"2026101503085406100_bib18","doi-asserted-by":"publisher","first-page":"38244","DOI":"10.1038\/srep38244","article-title":"Relaxation oscillations and hierarchy of feedbacks in MAPK signaling","volume":"7","author":"Kocha\u0144czyk","year":"2017","journal-title":"Sci Rep"},{"key":"2026101503085406100_bib19","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.chembiol.2011.04.011","article-title":"In situ kinase profiling reveals functionally relevant properties of native kinases","volume":"18","author":"Patricelli","year":"2011","journal-title":"Chem Biol"},{"key":"2026101503085406100_bib20","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nbt1068","article-title":"A small molecule-kinase interaction map for clinical kinase inhibitors","volume":"23","author":"Fabian","year":"2005","journal-title":"Nat Biotechnol"},{"key":"2026101503085406100_bib21","doi-asserted-by":"publisher","first-page":"e0146021","DOI":"10.1371\/journal.pone.0146021","article-title":"Dose-response analysis using R","volume":"10","author":"Ritz","year":"2015","journal-title":"PLoS One"},{"key":"2026101503085406100_bib22","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1093\/bioinformatics\/btw354","article-title":"MultiQC: summarize analysis results for multiple tools and samples in a single report","volume":"32","author":"Ewels","year":"2016","journal-title":"Bioinformatics"},{"key":"2026101503085406100_bib23","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","article-title":"Salmon provides fast and bias-aware quantification of transcript expression","volume":"14","author":"Patro","year":"2017","journal-title":"Nat Methods"},{"key":"2026101503085406100_bib24","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2026101503085406100_bib25","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026101503085406100_bib26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/978-3-642-04898-2_132","article-title":"Bartlett\u2019s test","volume-title":"International encyclopedia of statistical science","author":"Arsham","year":"2011"},{"key":"2026101503085406100_bib27","doi-asserted-by":"publisher","DOI":"10.4135\/9781412961288","volume-title":"Encyclopedia of research design","author":"Lane","year":"2010"},{"key":"2026101503085406100_bib28","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1080\/01621459.1955.10501294","article-title":"A multiple comparison procedure for comparing several treatments with a control","volume":"50","author":"Dunnett","year":"1955","journal-title":"J Am Stat Assoc"},{"key":"2026101503085406100_bib29","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/01621459.1952.10483441","article-title":"Use of ranks in one-criterion variance analysis","volume":"47","author":"Kruskal","year":"1952","journal-title":"J Am Stat Assoc"},{"key":"2026101503085406100_bib30","volume-title":"Practical nonparametric statistics","author":"Conover","year":"1999","edition":"3rd edn"},{"key":"2026101503085406100_bib31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/00949657808810247","article-title":"An empirical comparison of the ANOVA F-test with alternatives which are more robust against heterogeneity of variance","volume":"8","author":"Levy","year":"1978","journal-title":"J Stat Comput Simulation"},{"key":"2026101503085406100_bib32","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1214\/aoms\/1177730491","article-title":"On a test of whether one of two random variables is stochastically larger than the other","volume":"18","author":"Mann","year":"1947","journal-title":"Ann Math Stat"},{"key":"2026101503085406100_bib33","doi-asserted-by":"publisher","first-page":"4806","DOI":"10.1158\/1078-0432.CCR-12-0742","article-title":"First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK\/RAF inhibitor in patients with solid tumors","volume":"18","author":"Martinez-Garcia","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2026101503085406100_bib34","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/mc.20607","article-title":"KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach","volume":"49","author":"Yoon","year":"2010","journal-title":"Mol Carcinog"},{"key":"2026101503085406100_bib35","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1073\/pnas.0900780106","article-title":"(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway","volume":"106","author":"Pratilas","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026101503085406100_bib36","article-title":"Multi-disciplinary review and evaluation: NDA 210498, MEKTOVI (binimetinib)","author":"Patel","year":"2017"},{"key":"2026101503085406100_bib37","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1186\/1471-2407-10-363","article-title":"Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse","volume":"10","author":"Aulino","year":"2010","journal-title":"BMC Cancer"},{"key":"2026101503085406100_bib38","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/1758834015616934","article-title":"Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy","volume":"8","author":"Eroglu","year":"2016","journal-title":"Ther Adv Med Oncol"},{"key":"2026101503085406100_bib39","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1186\/s12885-017-3529-5","article-title":"Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care","volume":"17","author":"Heppt","year":"2017","journal-title":"BMC Cancer"},{"key":"2026101503085406100_bib40","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.21037\/tlcr-20-455","article-title":"KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples","volume":"9","author":"Loong","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"2026101503085406100_bib41","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1056\/NEJMc2030638","article-title":"Distribution of KRAS (G12C) somatic mutations across race, sex, and cancer type","volume":"384","author":"Nassar","year":"2021","journal-title":"N Engl J Med"},{"key":"2026101503085406100_bib42","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jtho.2018.12.013","article-title":"K-ras mutation subtypes in NSCLC and associated co-occuring mutations in other oncogenic pathways","volume":"14","author":"Scheffler","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2026101503085406100_bib43","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/psp4.12175","article-title":"Population pharmacokinetics of selumetinib and its metabolite N-desmethyl-selumetinib in adult patients with advanced solid tumors and children with low-grade gliomas","volume":"6","author":"Patel","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2026101503085406100_bib44","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S1470-2045(12)70270-X","article-title":"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial","volume":"13","author":"Infante","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026101503085406100_bib45","doi-asserted-by":"publisher","first-page":"S930","DOI":"10.1016\/j.annonc.2024.08.1587","article-title":"1524P preliminary phase I safety and activity of IMM-1-104, an orally dosed universal RAS inhibitor that drives deep cyclic inhibition of the MAPK pathway at MEK, in patients with advanced unresectable or metastatic solid tumors","volume":"35","author":"Chung","year":"2024","journal-title":"Ann Oncol"},{"key":"2026101503085406100_bib46","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.1158\/0008-5472.CAN-08-3658","article-title":"Adaptive therapy","volume":"69","author":"Gatenby","year":"2009","journal-title":"Cancer Res Jun"},{"key":"2026101503085406100_bib47","doi-asserted-by":"publisher","first-page":"e76284","DOI":"10.7554\/eLife.76284","article-title":"Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes","volume":"11","author":"Zhang","year":"2022","journal-title":"Elife"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-25-4907\/3812332\/can-25-4907.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-25-4907\/3817899\/can-25-4907.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/20\/5223\/3836895\/can-25-4907.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/20\/5223\/3836895\/can-25-4907.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:08:59Z","timestamp":1792048139000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/86\/20\/5223\/788687\/Dual-MEK-Inhibitor-Atebimetinib-Displays-Broad"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":47,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2026,7,21]]},"published-print":{"date-parts":[[2026,10,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-25-4907","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.34520000","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.34519976","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.34519979","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.34520003","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.34519967","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.34519973","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.34519994","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.34519961","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.34519985","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.34519982","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.34519970","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.34520006","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.8775248","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]}}}